Performance
Growth Hormone Axis
Limited
Banned in sport

IGF-1 LR3

Also known as Long R3 IGF-1 · IGF-1 Long Arg3

New

Reconstitution & dosing guide

0.1 mg · 1 mg vial sizes — research phases, recon steps, and a live unit calculator.

Open guide

Available sizes & price

Catalog only

100mcg x 10 vials

IGF-1 LR3 (IG01) · Not in current stock

$20 / vial

Add

1mg x 10 vials

IGF-1 LR3 (IG1) · Not in current stock

$50 / vial

Add

Prices per vial · Research use only · Not medical advice.

Long-acting IGF-1 analog used in bodybuilding research circles for hypertrophy; significant risk profile.

How to picture it

IGF-1 is the downstream growth message GH often works through. LR3 is engineered to last longer and bind less to inhibitory binding proteins, so the growth/repair signal stays available. Picture a longer-lasting IGF megaphone for muscle and tissue research — potent anabolic and recovery pathway engagement, and not a casual tool.

Research focus & benefits

  • Sustained IGF-1 pathway research
  • Anabolic and recovery model studies
  • Reduced binding-protein decoy effects vs native IGF-1

Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.

Overview

IGF-1 LR3 is a modified insulin-like growth factor-1 with reduced binding to IGF-binding proteins and an extended half-life. It is powerful, anabolic, and risky — hypoglycemia, organ growth concerns, and theoretical cancer promotion are central issues. Banned in sport.

Mechanism

Activates IGF-1 receptor signaling driving protein synthesis, satellite cell activity, and glucose uptake.

Research uses

  • Cell culture growth factor
  • Muscle hypertrophy research
  • IGF axis pharmacology

Research dosing notes

High-risk compound. Hypoglycemia management knowledge is essential in any clinical research context. Not beginner territory.

Open full reconstitution & dosing guide →

Half-life / kinetics

~20–30 hours (much longer than native IGF-1)

Common research routes

Intramuscular injection
Subcutaneous injection

Reported considerations

  • Hypoglycemia
  • Water retention
  • Carpal tunnel–like symptoms
  • Possible visceral organ growth
  • Theoretical oncogenic risk

Contraindications / cautions

  • Any cancer history
  • Uncontrolled diabetes
  • Pregnancy
  • Drug-tested athletes

Common research stacks

  • PEGs / MGF discussions
  • Insulin (extremely dangerous DIY territory)
  • GH secretagogues

Legal / access note

Unapproved for bodybuilding; WADA prohibited; research chemical legal gray areas apply.